<DOC>
	<DOCNO>NCT00860431</DOCNO>
	<brief_summary>1 . To evaluate effectiveness AST-120 ( spherical carbon adsorbent ) add standard-of-care therapy moderate severe Chronic Kidney Disease ( CKD III-IV ) , time first occurrence event triple composite outcome initiation renal replacement therapy , decline eGFR 50 % double serum creatinine ( sCr ) compare standard-of-care group ; 2 . To evaluate effectiveness AST-120 ( spherical carbon adsorbent ) GFR proteinuria ; 3 . To evaluate effectiveness AST-120 ( spherical carbon adsorbent ) health relate quality life ; 4 . To evaluate safety tolerability long-term AST-120 therapy patient CKD ; 5 . To evaluate all-cause mortality hospitalization apart plan operation intervention )</brief_summary>
	<brief_title>Kremezin Study Against Renal Disease Progression Korea</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>Informed consent Age 18 year old CKD stage 3,4 ( estimate GFR CockcroftGault equation 1559 mL/min/1.73m^2 ) Followed responsible nephrologists 6 month eGFR check 2 time screening period eGFR decline expected decline &gt; = 5mL/min/year &gt; =2.5mL/min/6 month Blood pressure &lt; = 160/100 mmHg Blood pressure check 3 time screening period No significant change medication CKD Patients take medicine AST120 ketosteril within 2 month Received investigational agent participate clinical study within previous 2 month History gastrointestinal disease ( active gastric ulcer , inflammatory bowel disease , hiatal hernia , severe GI dysmotility ) obstructive urologic disease reversible kidney diseases chronic kidney disease due autosomal dominant polycystic kidney disease , ADPKD severe nephrotic syndrome , 10g more/day ( random urine pCR &gt; = 10.0 ) History previous kidney transplant Heart failure ( NYHA IIIIV ) , uncontrolled arrhythmia , unstable angina Liver cirrhosis ( ChildPugh B , C ) active infection , uncontrolled inflammatory disease progressive malignant disease cerebral infarction intracranial hemorrhage within 6 month , except transient ischemic attack ( TIA ) uncontrolled blood sugar ( HbA1c &gt; 10 % ) severe anemia , Hb &lt; 7g/dL Life expectancy le 12 month point randomization Pregnant willing bear child study patient , inappropriate study ( researcher decide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>